Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration

Blanco-Colio, Luís Miguel; Martı́n-Ventura, José Luis; Teresa, Eduardo de; Farsang, Csaba; Gaw, Allan; Gensini, Gianfranco; Leiter, Lawrence A.; Langer, Anatoly; Martineau, Pierre; Egido, Jesús

doi:10.1016/j.ahj.2007.02.029

Cited by 76 publications

(43 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,25 Similarly, changes in these cytokine levels have been involved in the pathogenesis of type 2 diabetes and cardiovascular diseases, both diseases highly linked with obesity. 25,26 We have observed that one of the main effects of FA1 on human monocytes and adipocytes cell lines in vitro is to enhance the expression of some proinflammatory cytokines. In support of our findings, several studies have shown that FA1 is also involved in the mediation of the immunoresponse.…”

Section: Discussionmentioning

confidence: 99%

Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro

et al. 2008

View full text Add to dashboard Cite

Objective: To investigate fetal antigen 1 (FA1) protein within the context of human obesity and its relation with insulin sensitivity. Subjects: Cross-sectional study that analyses circulating levels of FA1 in two selected human cohorts: n ¼ 127 men for the study of FA1 circulating levels in the context of obesity and insulin sensitivity (S i ); and n ¼ 61 severely obese women before and after bariatric surgery. The response in vitro to FA1 protein on human cell lines of monocytes, preadipocytes and mature adipocytes was studied. Measurements: Anthropometrical parameters: body mass index, waist-to-hip ratio, waist circumference, fat-free mass and fat mass. Clinical parameters: lipid profile (high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides), glycemic profile (fasting glucose, insulin, S i , HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), cytokines (sIL-6), adipokines (adiponectin) and circulating soluble fractions of tumor necrosis factor-a receptors 1 and 2 (sTNFR1 and sTNFR2). Results: In the obesity study, levels of FA1 in serum were found to increase with obesity. The S i index was negatively dependent on FA1 levels. In severe obesity, serum levels of FA1 decreased 1.4-fold 6 months after bariatric surgery. In vitro assays with FA1 protein on human monocytes and adipocytes cell lines modified the expression of pro-inflammatory cytokines and adipokines (tumor necrosis factor-a (TNFa), monocyte chemoattractant protein-1 (MCP-1), IL-6 (interleukin-6) and adiponectin). Conclusion: FA1 serum levels were increased in obese subjects and might influence S i . The stimulatory effect of FA1 protein on pro-inflammatory cytokines on both immune and adipose cell types could contribute to worsening the inflammatory environment observed in obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro

et al. 2008

View full text Add to dashboard Cite

show abstract

“…14,22,23 In addition, evidence suggests that the 2 agents may differ in their nonlipid effects, such as the reduction in inflammation. 24 The association between inflammatory markers and cardiovascular events has received increased attention after the publication of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin), in which rosuvastatin therapy was shown to benefit patients with normal low-density lipoprotein cholesterol levels (<130 mg/dL) but elevated levels of the inflammatory marker C-reactive protein. 25 Multiple studies have shown that atorvastatin significantly reduces high-sensitivity C-reactive protein levels, 26-29 whereas a study of simvastatin found reductions of smaller magnitude, 30 and a comparative study found that atorvastatin was associated with greater high-sensitivity C-reactive protein reductions compared with simvastatin.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population

Simpson

Signorovitch

Birnbaum

et al. 2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…On the other hand, it is more likely that the reduction of myocardial ischemia was not solely due to LDL lowering. Recent studies indicate that statins among many other effects are able to modulate inflammation in the vessel wall and enhance neovascularization (22). Antiischemic effect of lovastatin treatment may be attributed to complex influence of statins on process of coronary atherogenesis, endothelial function, stabilization of plaques and antiinflammatory, anti-thrombotic, and anti-arrhythmic properties.…”

Section: Discussionmentioning

confidence: 99%

Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease

Kerimkulova

Lunegova²,

Gotfrid³

et al. 2011

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

ÖZETAmaç: Koroner arter hastalığı (KAH) ve dislipidemili hastalardaki iskemi ve miyokart yeniden şekillenme üzerine statinlerin yararlı etkileri olduğu kanıtlanmıştır. Amacımız, lovastatinin sol ventrikül (SV) sistolik ve diyastolik fonksiyonları ile miyokart iskemisi üzerine olası ve doğrudan yararlı etkilerini araştırmaktı. Yöntemler: Bu randomize prospektif çalışma, koroner arter ve dislipidemi hastalığı olan 83 hastadan (46 erkek; ortalama yaş, 54.3±6.5 yıl) oluş-maktadır. Bütün hastalar, gruplara randomizeydi: 1. grup (N= 44), 20-60 mg/gün lovastatin aldı, hipolipidemik diyet ve beden eğitimi uygulandı; 2. grup (N=39) -hipolipidemik diyet ve beden eğitimi uygulandı. ABSTRACTObjective: Emerging evidence assumes that statins have a benefit to influence the myocardial remodeling and ischemia in patients with coronary artery disease (CAD). Our aim was to investigate the possible and direct favorable effects of lovastatin on left ventricular (LV) systolic, diastolic function and myocardial ischemia in patients with CAD. Methods: This randomized prospective study consisted of 83 patients (46 males; mean age 54.3±6.5 years) with CAD and dyslipidemia. All patients were randomized to following groups: the 1st group (n=44) received lovastatin (20-60 mg/day), hypolipidemic diet and physical training; the 2 nd group (n=39) -hypolipidemic diet and physical training. Lipid spectrum, Doppler-echocardiography, bicycle exercise test and 24-hour ambulatory electrocardiographic monitoring were done at baseline and were repeated after 12 months of treatment. The data were analyzed by using the paired and unpaired Student's t-tests. Results: In the 1 st group there was an improvement of lipid spectrum (p<0.05) without significant changes of liver transaminases and other side effects. After treatment LV ejection fraction increased from 59.8±8.04 to 62.9±4.43% in lovastatin alone group (p=0.01). Unlike 2 nd group, the 1 st group's patients had also reduction of myocardial ischemia: increased exercise time (5.21±1.81 vs.

show abstract

Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration

Cited by 76 publications

References 39 publications

Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro

Human serum levels of fetal antigen 1 (FA1/Dlk1) increase with obesity, are negatively associated with insulin sensitivity and modulate inflammation in vitro

Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population

Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease

Contact Info

Product

Resources

About